TEE
CNCE

Tibra Equities Europe’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Tibra Equities Europe’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-82,500
Closed -$348K – 233
2021
Q2 		$348K Buy
+82,500
New +$349K 0.11% 64

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Tibra Equities Europe's CNCE Position: Q3 2021 in Review

Tibra Equities Europe sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2021, closing a stake of 82,500 shares — an estimated $348K sold.

Tibra Equities Europe first reported a position in CNCE in Q2 2021 and held it in 1 quarter. The position peaked at $348K in Q2 2021. 61 funds tracked by Wall St. Rank hold CNCE as of Q3 2021.

  • Tibra Equities Europe reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 82,500 Concert Pharmaceuticals, Inc. shares in Q3 2021, an estimated $348K.
  • Tibra Equities Europe first reported a position in Concert Pharmaceuticals, Inc. in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Concert Pharmaceuticals, Inc. position peaked at $348K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.